Facilitation of Contextual Fear Extinction by Orexin-1 Receptor Antagonism Is Associated with the Activation of Specific Amygdala Cell Subpopulations

África Flores, PhD; Cyril Herry, PhD; Rafael Maldonado, MD, PhD; Fernando Berrendero, PhD

Laboratory of Neuropharmacology, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain (Drs Flores, Maldonado, and Berrendero); INSERM, Neurocentre Magendie, Bordeaux, France (Dr Herry); University Bordeaux, Neurocentre Magendie, Bordeaux, France (Dr Herry); Faculty of Experimental Sciences, Universidade Francisco de Vitoria, Madrid, Spain (Dr Berrendero).

Correspondence: Rafael Maldonado, MD, PhD, Laboratory of Neuropharmacology, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, PRBB, C/ Doctor Aiguader 88, 08003 Barcelona, Spain (rafael.maldonado@upf.edu); and Fernando Berrendero, PhD, Faculty of Experimental Sciences, Universidad Francisco de Vitoria, 28223 Pozuelo de Alarcón, Madrid, Spain (fernando.berrendero@ufv.es).

Abstract

Background: Orexins are hypothalamic neuropeptides recently involved in the regulation of emotional memory. The basolateral amygdala, an area orchestrating fear memory processes, appears to be modulated by orexin transmission during fear extinction. However, the neuronal types within the basolateral amygdala involved in this modulation remain to be elucidated.

Methods: We used retrograde tracing combined with immunofluorescence techniques in mice to identify basolateral amygdala projection neurons and cell subpopulations in this brain region influenced by orexin transmission during contextual fear extinction consolidation.

Results: Treatment with the orexin-1 receptor antagonist SB334867 increased the activity of basolateral amygdala neurons projecting to infralimbic medial prefrontal cortex during fear extinction. GABAergic interneurons expressing calbindin, but not parvalbumin, were also activated by orexin-1 receptor antagonism in the basolateral amygdala.

Conclusions: These data identify neuronal circuits and cell populations of the amygdala associated with the facilitation of fear extinction consolidation induced by the orexin-1 receptor antagonist SB334867.

Keywords: fear extinction, orexin, amygdala, retrograde labeling, calbindin

Introduction

Orexins (also known as hypocretins) are hypothalamic neuropeptides that activate 2 different G-protein coupled receptors: orexin type 1 (OX1R) and 2 (OX2R) (de Lecea et al., 1998; Sakurai et al., 1998). Orexin-expressing neurons are exclusively located in the lateral hypothalamus, but they have extensive projections throughout the brain (Peyron et al., 1998). The orexin system is involved in multiple physiological functions (Li et al., 2014), including the modulation of emotional memory (Flores et al., 2015).

Clinical research showed a reduced amygdala activity during aversive conditioning in human narcolepsy (Ponz et al., 2010), a pathophysiological condition associated with a loss of orexin neurons (Peyron et al., 2000). Pharmacological blockade or genetic deletion of OX1R impaired contextual and cued fear conditioning (Sears et al., 2013; Soya et al., 2013; Flores et al., 2014; Wang et al., 2017) in rodents. Moreover, OX1R antagonism facilitated the consolidation of both contextual and cued fear.
were placed in the conditioning chamber for 3 minutes before the training day, mice connected to a scrambled shock generator. On the training day, mice placed on the floor was constructed of parallel stainless-steel bars and connected to a scrambled shock generator (Imetronic). SB334867 or vehicle was administered immediately after the first extinction session (E1), targeting the consolidation phase of fear extinction.

**Methods**

**Animals**

Male C57BL6/j mice (12 weeks old, Janvier) were individually housed for 7 days prior to experiments and provided with food and water ad libitum. Housing was maintained at constant temperature (21 ± 1°C) and humidity (55 ± 10%) under a 12-h-light/-dark cycle, and all studies were performed during the light phase. All animal procedures were conducted in accordance with standard ethical guidelines (European Communities Directive 86/609-EEC) and were approved by the committee on Animal Health and Care of Institut National de la Santé et de la Recherche Médicale and French Ministry of Agriculture and Forestry (agreement A3312001).

**Drugs**

The OX1R antagonist SB334867 (5 mg/kg) (Tocris) was dissolved in 1% (wt/vol) 2-hydroxypropyl-β-cyclodextrin (Sigma-Aldrich) and 10% dimethyl-sulfoxide (vol/vol) in distilled water, and administered by i.p. route (5 mL/kg).

**Contextual Fear Extinction**

Mice were fear conditioned in a shuttle chamber surrounded by a larger sound-attenuating cabinet (Imetronic). The shuttle chamber floor was constructed of parallel stainless-steel bars and connected to a scrambled shock generator. On the training day, mice were placed in the conditioning chamber for 3 minutes before the exposure to an unconditioned stimulus (US, 0.6-mA footshock for 2 s) and then remained in the chamber for 1 minute. Testing was performed during 2 extinction trials (E1 and E2 at 24 and 48 hours after the training, respectively) by scoring freezing behavior during the first 3 minutes of a 5-minute exposure to the conditioning chamber. Freezing, a rodent’s natural response to fear (LeDoux, 1993), was defined as the absence of movement and was scored by an automated infrared beam detection system located on the bottom of the experimental chambers (Imetronic). SB334867 or vehicle was administered immediately after the first extinction session (E1), targeting the consolidation phase of fear extinction.

**Immunofluorescence and Imaging**

**Tissue Preparation**

Two hours after the second extinction trial (E2), retrobead-injected mice were transcardially perfused with 4% paraformaldehyde, postfixed in the same fixative for 24 hours (4°C), and cryoprotected in a solution of 30% sucrose at 4°C. Coronal frozen sections containing the BLA (from –1.22 mm to –1.82 mm relative to bregma) and the mPFC (from +1.98 mm to +1.54 mm relative to bregma) were made at 30 μm on a freezing microtome and stored in a 5% sucrose solution at 4°C until use. Slices containing the caudal and middle BLA regions were selected for immunofluorescence processing.

**Injection Site Verification**

Serial mPFC coronal sections were mounted onto glass slides. Low-magnification images from all slices showing retrobead transport were captured using a Zeiss fluorescent microscope, and retrobead injection sites were histologically verified by overlapping to standard stereotaxic plates (Paxinos and Franklin, 2001). Only animals with retrobead presence circumscribed into the PL or the IL were included in statistical analysis of c-Fos expression within retrolabeled neurons (12 of 23 mice).

**Immunofluorescence**

Free-floating BLA slices were rinsed in 0.1 M PB, blocked in a solution containing 3% normal goat serum and 0.3% Triton X-100 in 0.1 M PB and incubated overnight at 4°C with a primary antibody (rabbit polyclonal anti-c-Fos, Sigma-Aldrich). Following three washes in 0.1 M PB, slices were incubated for 2 h at room temperature with a secondary antibody (Cy3 goat anti-rabbit, Jackson Immunoresearch) diluted 1:300 in 0.1 M PB containing 3% normal goat serum and 0.3% Triton X-100. Sections were then washed and mounted onto glass slides with 1% Vectorshield (Vector Laboratories). Sections were analyzed using a Zeiss 510 confocal microscope (Carl Zeiss, Jena, Germany).
0.1M PB (NGS-T-PB) at room temperature for 2 hours, and incubated overnight at 4°C in the same solution with the primary antibody. Next day, after 3 rinses in 0.1 M PB, sections were incubated with the secondary antibody at room temperature in NGS-T-PB for 2 hours. After incubation, sections were rinsed and mounted immediately after onto glass slides coated with gelatine in Mowiol mounting medium. We used the following primary antibodies: anti-c-Fos (1:500, rabbit, sc-72, Santa Cruz Biotechnology), anti-PV (1:500, guinea pig, Synaptic Systems), and anti-CB (1:500, mouse, Synaptic Systems). As secondary antibodies, we employed AlexaFluor-647 goat anti-rabbit (1:500, Life Technologies), AlexaFluor-555 goat anti-guinea pig (1:500, ThermoFisher), and AlexaFluor-488 goat anti-mouse (1:500, Jackson Immunoresearch).

**Image Analysis**

Confocal images were obtained using a Leica TCS SP5 confocal microscope (20× objective) (Leica Microsystems). Three-dimensional z stacks were acquired using 3 different laser lines (488, 561, and 633 nm), sectioned in 4-μm thin optical planes along 16 to 20 μm (5–6 planes). Two-dimensional overview pictures (8 bit, 1024 × 1024 pixels) were obtained by z projection and further analyzed in ImageJ software (6 sections per animal). Expression of c-Fos was determined bilaterally within the BLA using a fixed threshold interval (n = 11–12 mice/group). Colocalization of c-Fos with red or green retrobead positive neurons (n = 6 mice/group), as well as with PV or CB positive neurons (n = 9 mice/group), was quantified using the ImageJ manual particle counting option. PV and CB were analyzed unilaterally to avoid retrobead detection.

**Statistical Analysis**

Repeated-measures 2-way ANOVA was employed to analyze freezing behavior, followed by Fisher LSD posthoc test. Unpaired Student’s t test was used in histological experiments to compare vehicle- and SB334867-treated groups. The level of significance was P < 0.05 in all experiments.

**Results**

**Treatment with the OX1R Antagonist SB334867 Is Associated with Increased Activity of BLA Neurons Projecting to IL during Fear Extinction**

Mice were injected unilaterally into the PL and IL with 2 different retrobeads coated with red or green fluorophores (Figure 1A and E) to assess whether orexin antagonism modifies the activation pattern of the putative fear (PL-projecting) and extinction (IL-projecting) neurons present in the BLA (Senn et al., 2014) during contextual fear extinction. After 4 weeks of recovery to allow sufficient axonal retrobead transport, mice underwent a contextual fear conditioning and extinction procedure. Freezing behavior was scored during the first extinction session (E1), mice were treated with SB334867 (5 mg/kg, i.p.) or vehicle immediately after, and 24 h later (second extinction session, E2) freezing was measured again (Figure 1A). As previously reported (Flores et al., 2014), OX1R antagonism was able to modify the course of contextual fear extinction as shown by 2-way ANOVA (treatment x day: F2,28 = 5.90; P < 0.05). Thus, SB334867-treated mice showed reduced levels of freezing at E2 compared with the vehicle group (P < 0.05) (Figure 1B), confirming the enhanced consolidation of fear extinction induced by OX1R blockade (Flores et al., 2014). Immunofluorescence processing of the BLA after E2 revealed an increase of c-Fos expression in SB334867-treated mice (P < 0.01) (Figure 1C–D). Successful retrograde labeling was then confirmed by red and green retrobead detection in different projection neurons located within the BLA (Figure 1F), which resulted similarly in SB334867- and vehicle-treated groups (Figure 1G). Notably, analysis of retrobead and c-Fos coexpression showed an increased activity of BLA neurons targeting the IL (P < 0.01) (Figure 1F) in mice injected with SB334867, suggesting that OX1R blockade facilitates the recruitment of these extinction-promoting projection neurons. In contrast, no significant changes between groups were observed in the activity of PL-projecting neurons (Figure 1F). In addition, the number of nonretroabeled c-Fos positive neurons in the BLA was higher in the SB334867 group than in the vehicle-treated group (P < 0.01) (Figure 1H), suggesting that the OX1R antagonist is enhancing as well the activation of other neurons than those projecting to the IL (e.g., local interneurons). The total number of retrobead+, c-Fos+, and double-positive cells of each experimental condition is shown in supplementary Table 1.

**OX1R Blockade Enhances the Activation of Local Interneurons Containing CB, but Not PV, within the BLA during Fear Extinction**

To identify which other BLA neuronal populations are activated upon OX1R blockade during fear extinction, we investigated the 2 most abundant groups of local interneurons within this brain area: those containing the calcium-binding proteins PV and CB. These cell subpopulations are mainly nonpyramidal GABAergic interneurons (McDonald and Mascagni, 2001) and are involved in fear and anxiety processes (Butler et al., 2011; Wolff et al., 2014). In agreement with previous studies, approximately 80% of PV neurons exhibited colocalization with CB, and the number of neurons expressing PV and/or CB was not modified in mice treated with the OX1R antagonist (Figure 2A). Interestingly, mice treated with SB334867 displayed higher expression of c-Fos within those nonpyramidal neurons containing CB only compared with control animals (P < 0.01) (Figure 2B). This effect was not observed in either the neuronal population expressing PV or both PV and CB (Figure 2B). The total number of CB+, PV+, and c-Fos+ cells, and double-/triple-stained cells for each experimental condition is shown in supplementary Table 2. Other projection cells or inhibitory interneurons within the BLA could likewise be activated due to orexin antagonism during fear extinction, since c-Fos expression also increased in neurons that do not express CB or PV in SB334867-treated mice (P < 0.01) (supplementary Table 2).

**Discussion**

Our results identify specific neuronal subpopulations within the BLA associated with enhanced consolidation of fear extinction induced by OX1R blockade. Thus, the OX1R antagonist SB334867 increased the recruitment of BLA projection neurons targeting the IL during the ensuing fear extinction trial. Moreover, GABAergic interneurons related to fear modulation that express the calcium-binding protein CB, but not PV, were activated by OX1R antagonism during this process.

Several recent reports have revealed a role for the orexin system in the regulation of emotional memories (Flores et al., 2015). OX1R blockade facilitates the consolidation of fear extinction (Flores et al., 2014), suggesting a potential usefulness of OX1R antagonists for the treatment of anxiety disorders associated with fear deregulation, such as phobias or post-traumatic stress disorder. In agreement, the activation level of hypothalamic orexin neurons appears to be negatively correlated with successful extinction of cue-conditioned fear in rodents (Sharko et al., 2016). The BLA is a pivotal brain region.
for processing fear, and decreased activity of this structure has been linked to impairment of fear extinction (Holmes and Singewald, 2013). Accordingly, the extinction-facilitating effects of the OX1R antagonist SB334867 were associated with increased c-Fos expression in the BLA, as previously reported (Flores et al., 2014).

The BLA and the mPFC are interconnected brain structures involved in the acquisition and extinction of conditioned fear (Dejean et al., 2015). The IL subdivision of the mPFC plays a crucial role in extinction memory consolidation, while the adjacent PL subdivision has been implicated in sustained fear expression and resistance to extinction (Sierra-Mercado et al., 2011).
Recently, an elegant study using retrograde tracing and optogenetic approaches has revealed the existence of distinct subpopulations of BLA projection neurons to the mPFC in fear expression and extinction (Senn et al., 2014). BLA neurons projecting to PL are active during high states of fear, whereas BLA neurons targeting the IL are recruited during fear extinction (Senn et al., 2014). Notably, we observed an enhancement in the activation of BLA neurons projecting to IL, but not to PL, in mice treated with SB334867 during fear extinction. In agreement, OX1R antagonism has been reported to increase IL activation during this behavioral response (Flores et al., 2014). These results suggest that the facilitation of fear extinction consolidation induced by OX1R antagonism is associated with the recruitment of this BLA-IL neuronal circuit.

Figure 2. OX1R antagonism increases c-Fos expression in calbindin (CB)+ neurons within the basolateral amygdala (BLA) during fear extinction. A, Total number of CB+ neurons, parvalbumin (PV)+ neurons, and coexpressing CB+ PV+ neurons per slice detected within the BLA (n = 9 mice/group). Representative images showing CB+ (green), PV+ (red), and CB+PV+ (yellow) immunofluorescence is also displayed (lower panels). B. Percentage of c-Fos+ neurons among those expressing only CB, only PV, or coexpressing CB and PV. Representative images showing c-Fos (purple) expression within CB+ (green) neurons is also displayed (lower panels). Arrows indicate CB+ neurons expressing c-Fos. Scale bars represent 200 μm. **P<.01 between treatments.
Nonpyramidal GABAergic interneurons within the BLA can be divided considering the content of several calcium-binding proteins such as CB and/or PV (McDonald and Mascagni, 2001). These cell subtypes have been previously involved in the regulation of fear behaviors (Butler et al., 2011; Wolff et al., 2014) and could differentially modulate neuronal circuits related to fear conditioning and extinction processes. The administration of SB334867 increased the activation of neurons containing CB, but not PV, during the extinction of fear. In agreement, activation of CB-expressing interneurons appears to be inversely correlated with fear expression (Butler et al., 2014). Thus, rats exposed to predator odor displayed increased fear responses and reduced c-Fos expression in CB+ neurons in the BLA (Butler et al., 2011). PV neurons were not affected by the exposition to the same predator threat (Butler et al., 2011). Together, these data suggest that declined fear expression during the extinction process induced by OX1R antagonism could be due to the activation of local BLA interneurons expressing CB. Nevertheless, intra-amygdalar microcircuits are still poorly understood, and hence it remains to be elucidated whether this increased activity of CB-expressing interneurons by OX1R blockade is related to the modulation of the BLA-IL circuit.

In conclusion, these data enhance our knowledge of the amygdala circuitry involved in the facilitation of fear extinction induced by OX1R antagonism. Such understanding will contribute to refine future therapeutic approaches for anxiety disorders characterized by pathological fear.

**Acknowledgments**

This work was supported by “Plan Nacional sobre Drogas” (no. 2014I019 to F.B.), the “Ministerio de Economía y Competitividad-MINECO” (no. SAF2014-59464-P to R.M.), the “Instituto de Salud Carlos III” (no. PI13/00042 to F.B. and RETICS-RTA, no. RD12/0028/0023 to R.M.), the “Generalitat de Catalunya-AGAUR” (no. 2014-SGR-1547 and ICREA-Acadèmia (2015) to R.M.). RD12/0028/0023 to R.M.), the “Generalitat de Catalunya-AGAUR” (no. 2014-SGR-1547 and ICREA-Acadèmia (2015) to R.M.). AF was recipient of an EMBO Short-Term Fellowship (281-2015).

**Statement of Interest**

None.

**References**


